3-Month paliperidone palmitate for preventing relapse in schizophrenia
Black-box warning in dementia. As with all atypical antipsychotics, the black-box warning for PPM-3 states that it is not approved for, and should not be used in, patients with dementia-related psychosis. An analysis of placebo-controlled studies revealed that patients taking an antipsychotic had (1) 1.6 to 1.7 times the risk of death than those who received placebo and (2) a higher incidence of cerebrovascular adverse reactions.
Adverse reactions
The safety profile of PPM-3 is similar to that of PPM-1. The most common adverse reactions are:
• reaction at the injection site
• weight gain
• headache
• upper respiratory tract infection
• akathisia
• parkinsonism.
See the full prescribing information for a complete list of adverse effects.
Related Resources
• Sedky K, Nazir R, Lindenmayer JP, et al. Paliperidone palmitate: once monthly treatment option for schizophrenia. Current Psychiatry. 2010;9(3):48-49.
• Berwaerts J, Liu Y, Gopal S, et al. Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial [published online March 29, 2015]. JAMA Psychiatry. doi: 10.1001/jamapsychiatry.2015.0241.
Drug Brand Names
Paliperidone palmitate • Invega Sustenna, Invega Trinza
Risperidone • Risperdal
